To include your compound in the COVID-19 Resource Center, submit it here.

Immunomedics reports updated Phase II data for sacituzumab govitecan in TNBC

Immunomedics Inc. (NASDAQ:IMMU) reported updated data from a cohort of 110 patients with relapsed or refractory metastatic triple-negative breast cancer (TNBC) in the Phase II portion of the Phase I/II

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE